) For the five-year period of requested support, we propose to discover and develop novel anticancer agents derived from natural product sources, using the specific approaches shown below. 1. Acquire and screen a diverse range of natural product extracts from several sources to allow for efficient drug discovery, with approximately 9000 extracts/year from the Council for Scientific and Industrial Research (CSIR) in South Africa and approximately 300 extracts/year from the Institute for Crop and Food Research (CFR) of New Zealand, both countries with a high rate of endemism and biodiversity """"""""hotspots"""""""" 2. Discover new bioactive natural product extracts with mechanisms of action that are known to be therapeutically important by mining the National Cancer Institute's (NCI) Division of Therapeutics in-house database and by using selective yeast bioassays by using the COMPARE algorithm to identify extracts in the NCI repository that have the same mechanism of action as topotecan, a known topoisomerase I inhibitor, or etoposide, a clinically important topoisomerase II inhibitor. Activity will be confirmed by the use of yeast-based assays to confirm topoisomerase I and II inhibitors. 3. Collaborate with SmithKline Beecham to discover additional topoisomerase I and II inhibitors and additional DNA-damaging agents by screening all available extract banks with a selective yeast bioassay. 4. Discover new bioactive natural products with novel mechanisms of action against a range of new targets using bioasssays newly developed at SmithKline Beecham Pharmaceuticals. Targets of interest include Myt1 kinase, checkpoint kinases 1 and 2, polo-like kinase, protein kinase B, tie2 receptor tyrosine kinase, vas protease, and histone deacetylases 3 and 4. 5. Carry out drug discovery on active extracts by fractionation of the confirmed active extracts against the appropriate bioassay and isolation and structure elucidation of the isolated active compounds, 6. Characterize the mode of action of the isolated active compounds in collaboration with SmithKline Beecham and the University of Virginia. 7. Obtain adequate quantities of agents identified above for in vivo testing in animal tumor models. 8. Provide extracts from the South African and New Zealand collections to Program 3 for fractionation when there is insufficient capacity in Associate Program 2.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA050771-12
Application #
6505544
Study Section
Project Start
2001-09-26
Project End
2002-05-31
Budget Start
Budget End
Support Year
12
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Cao, Shugeng; Murphy, Brian T; Foster, Caleb et al. (2009) Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem 17:2276-81
Clement, Jason A; Li, Mei; Hecht, Sidney M et al. (2006) Bioactive isomalabaricane triterpenoids from Rhabdastrella globostellata that stabilize the binding of DNA polymerase beta to DNA. J Nat Prod 69:373-6
Cao, Shugeng; Foster, Caleb; Brisson, Marni et al. (2005) Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorg Med Chem 13:999-1003
Cao, Shugeng; Foster, Caleb; Lazo, John S et al. (2005) Four diterpenoid inhibitors of Cdc25B phosphatase from a marine anemone. Bioorg Med Chem 13:5830-4
Chaturvedula, V S Prakash; Gao, Zhijie; Jones, Shannon H et al. (2004) A new ursane triterpene from Monochaetum vulcanicum that inhibits DNA polymerase beta lyase. J Nat Prod 67:899-901
Chaturvedula, V S Prakash; Zhou, Bing-Nan; Gao, Zhijie et al. (2004) New lupane triterpenoids from Solidago canadensis that inhibit the lyase activity of DNA polymerase beta. Bioorg Med Chem 12:6271-5
Prakash Chaturvedula, V S; Hecht, Sidney M; Gao, Zhijie et al. (2004) New neolignans that inhibit DNA polymerase beta lyase. J Nat Prod 67:964-7
Prakash Chaturvedula, V S; Gao, Zhijie; Hecht, Sidney M et al. (2003) A new acylated oleanane triterpenoid from Couepia polyandra that inhibits the lyase activity of DNA polymerase beta. J Nat Prod 66:1463-5
Prakash Chaturvedula, V S; Schilling, Jennifer K; Johnson, Randall K et al. (2003) New cytotoxic lupane triterpenoids from the twigs of Coussarea paniculata. J Nat Prod 66:419-22
Zhou, B N; Johnson, R K; Mattern, M R et al. (2001) The first naturally occurring Tie2 kinase inhibitor. Org Lett 3:4047-9

Showing the most recent 10 out of 14 publications